LLY
Healthcare
Eli Lilly (LLY): Two Drugs Drove 88% Of Growth, EPS Hit By $4.57 R&D
Lilly’s revenue grew 39% and guidance rose, but two drugs supplied 88% of growth, price fell 15%, and $4.57 a share of acquired R&D held non-GAAP EPS growth to 7%.